Trial Profile
A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Giant lymph node hyperplasia; Lymphoid leukaemia; Multiple myeloma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Centocor
- 01 Dec 2011 Actual end date (April 2011) added as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2010 Planned end date changed from 1 Jun 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.